Matrix metalloproteinases: protective roles in cancer
- PMID: 21418514
- PMCID: PMC4373327
- DOI: 10.1111/j.1582-4934.2011.01302.x
Matrix metalloproteinases: protective roles in cancer
Abstract
The original notion that matrix metalloproteinases (MMPs) act as tumour and metastasis-promoting enzymes by clearing a path for tumour cells to invade and metastasize has been challenged in the last decade. It has become clear that MMPs are involved in numerous steps of tumour progression and metastasis, and hence are now considered to be multifaceted proteases. Moreover, more recent experimental evidence indicates that some members of the MMP family behave as tumour-suppressor enzymes and should therefore be regarded as anti-targets in cancer therapy. The complexity of the pro- and anti-tumorigenic and -metastatic functions might partly explain why broad-spectrum MMP inhibitors failed in phase III clinical trials. This review will provide a focussed overview of the published data on the tumour-suppressive behaviour of MMPs.
© 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.
Similar articles
-
Matrix metalloproteinase inhibitors.Invest New Drugs. 1997;15(1):61-75. doi: 10.1023/a:1005722729132. Invest New Drugs. 1997. PMID: 9195290 Review.
-
Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions.Biochim Biophys Acta. 2010 Jan;1803(1):103-20. doi: 10.1016/j.bbamcr.2009.09.017. Epub 2009 Oct 2. Biochim Biophys Acta. 2010. PMID: 19800930 Free PMC article. Review.
-
Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies.Int J Dev Biol. 2004;48(5-6):411-24. doi: 10.1387/ijdb.041811af. Int J Dev Biol. 2004. PMID: 15349816 Review.
-
Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.Expert Opin Drug Metab Toxicol. 2016;12(2):191-200. doi: 10.1517/17425255.2016.1131820. Epub 2016 Jan 11. Expert Opin Drug Metab Toxicol. 2016. PMID: 26852787 Review.
-
Strategies for MMP inhibition in cancer: innovations for the post-trial era.Nat Rev Cancer. 2002 Sep;2(9):657-72. doi: 10.1038/nrc884. Nat Rev Cancer. 2002. PMID: 12209155 Review.
Cited by
-
Dual roles of myeloid-derived suppressor cells in various diseases: a review.Arch Pharm Res. 2024 Jul;47(7):597-616. doi: 10.1007/s12272-024-01504-2. Epub 2024 Jul 15. Arch Pharm Res. 2024. PMID: 39008186 Review.
-
MMPs-related risk model identification and SAA1 promotes clear cell renal cell carcinoma migration via ERK-AP1-MMPs axis.Sci Rep. 2024 Apr 24;14(1):9411. doi: 10.1038/s41598-024-59112-5. Sci Rep. 2024. PMID: 38658579 Free PMC article.
-
Deciphering the role of wound healing genes in skin cutaneous melanoma: Insights into expression, methylation, mutations, and therapeutic implications.Int Wound J. 2024 Apr;21(4):e14807. doi: 10.1111/iwj.14807. Int Wound J. 2024. PMID: 38591163 Free PMC article.
-
Identifying and validating MMP family members (MMP2, MMP9, MMP12, and MMP16) as therapeutic targets and biomarkers in kidney renal clear cell carcinoma (KIRC).Oncol Res. 2024 Mar 20;32(4):737-752. doi: 10.32604/or.2023.042925. eCollection 2024. Oncol Res. 2024. PMID: 38560573 Free PMC article.
-
Lung and blood perioperative metalloproteinases in patients undergoing oncologic lung surgery: Prognostic implications.Thorac Cancer. 2024 Feb;15(4):307-315. doi: 10.1111/1759-7714.15190. Epub 2023 Dec 28. Thorac Cancer. 2024. PMID: 38155459 Free PMC article. Clinical Trial.
References
-
- World Health Organization. World Cancer Report 2008. Lyon: World Health Organization; 2008.
-
- Danaei G, Vander HS, Lopez AD, et al. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005;366:1784–93. - PubMed
-
- Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002;115:3719–27. - PubMed
-
- Kruger A, Kates RE, Edwards DR. Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim Biophys Acta. 2010;1803:95–102. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources